In an effort to establish regulatory standards for CBD products, a coalition of CBD companies called ONE HEMP has presented a study to U.S. officials. The study demonstrates that consuming up to 70 milligrams of CBD per day is safe for healthy adults.
Additionally, the research suggests that those who are not trying to conceive, pregnant, or lactating can safely consume up to 160 milligrams of CBD daily. By engaging Congress and the Food and Drug Administration (FDA), the coalition aims to improve consumer protection through accurate product labeling and scientifically based safety limits.
The study by ToxStrategies LLC reveals that CBD’s recommended upper intake limits align with those set by leading regulatory bodies such as Health Canada, Australia’s Therapeutic Goods Administration, and the U.K.’s Food Standards Agency. It was peer-reviewed and published online on August 25 in Regulatory Toxicology and Pharmacology.
Charlotte’s Web: A Founding Member of ONE HEMP Calls for Stricter Standards
Charlotte’s Web, a founding member of ONE HEMP, emphasizes the importance of establishing scientifically-based safety limits and accurate product labeling to protect consumers. As the popularity of CBD products continues to grow, there is increasing concern about potential health risks due to inconsistent quality standards and labeling practices.
The company urges Congress to clarify the FDA’s mandate concerning CBD products and to implement more stringent regulatory standards. Accurate product labeling ensures that consumers have the necessary information to make informed decisions when purchasing and using CBD products.
Without clear guidelines from Congress and the FDA, consumers are left vulnerable to varying levels of product quality and potentially unreliable label claims.
Previous Studies on CBD Safety and Efficacy
Although the ONE HEMP study is among the first to offer a safe daily intake range for CBD, previous research has already demonstrated its safety profile and potential health benefits. A 2011 review published in the journal Current Drug Safety concluded that chronic use of CBD at high doses (up to 1500 milligrams per day) was generally well tolerated in humans.
Furthermore, clinical trials have shown promising results, with many studies indicating that CBD may help relieve symptoms of various health conditions. These include anxiety, sleep disorders, pain management, and certain types of epilepsy, such as Dravet Syndrome and Lennox-Gastaut Syndrome.
While more research is needed to determine optimal dosages and understand long-term effects, these findings support the favorable safety profile of CBD and suggest potential therapeutic applications.
The Push for Regulatory Standards in the CBD Industry
The need for regulatory standards within the CBD industry has become apparent as the market expands rapidly. Without FDA regulation, states have introduced their own guidelines and requirements concerning CBD product manufacturing, testing, labeling, and distribution. However, this patchwork approach leads to inconsistencies across state lines and does not adequately address potential public health risks. Consumers need access to accurate information about CBD products, and companies involved in manufacturing and marketing these products should also be held accountable for maintaining quality standards.
With clear federal guidelines, CBD companies can ensure they are providing safe, consistent products while promoting transparency and consumer trust. As Congress and the FDA consider establishing regulatory standards for CBD products, they must consider scientific evidence regarding the safe limits of CBD consumption presented by ONE HEMP and other reputable sources. By doing so, they will be better equipped to protect public health and facilitate informed decision-making among consumers and healthcare providers alike.